Publications - Visterra

Featured publications

Accelerating Characterization of Therapeutic Antibodies: A Comparative Assessment of icIEF-UV/MS and the Traditional Fractionation Workflow

July 28, 2025 | Journal of the American Society for Mass Spectrometry

Arnik Shah, et al.

Accelerating Characterization of Therapeutic Antibodies: A Comparative Assessment of icIEF-UV/MS and the Traditional Fractionation Workflow

Arnik Shah, Parth Shah, Alex Johnson, Jean Bender, Dmitry Gumerov, Jingwen Ding, Scott Mack, Matthew D. Stone, Maggie A. Ostrowski

>READ

A Phase 2 Trial of Sibeprenlimab in Patients with IgA Nephropathy

November 2, 2023 | The New England Journal of Medicine

Mohit Mathur, et al.

A Phase 2 Trial of Sibeprenlimab in Patients with IgA Nephropathy

Mohit Mathur, Jonathan Barratt, Bobby Chacko, Tak Mao Chan, Laura Kooienga, Kook-Hwan Oh, Manisha Sahay, Yusuke Suzuki, Muh Geot Wong, Jill Yarbrough, Jing Xia, Brian J G Pereira

>READ

Multi-omic single cell sequencing: Overview and opportunities for kidney disease therapeutic development

April 5, 2023 | Frontiers in Molecular Biosciences

Steven Pregizer, et al.

Multi-omic single cell sequencing: Overview and opportunities for kidney disease therapeutic development

Steven Pregizer, Thom Vreven, Mohit Mathur, Luke Robinson

>READ

Development of an antibody fused with an antimicrobial peptide targeting Pseudomonas aeruginosa: A new approach to prevent and treat bacterial infections

September 19, 2023 | PLOS Pathogens

Kenneth Johnson et al.

Development of an antibody fused with an antimicrobial peptide targeting Pseudomonas aeruginosa: A new approach to prevent and treat bacterial infections

Kenneth Johnson, James C. Delaney, Thomas Guillard, Fany Reffuveille, Jennifer Varin-Simon, Kai Li, Andrew Wollacott, Eric Frapy, Surin Mong, Hamid Tissire, Karthik Viswanathan, Faycal Touti, Gregory J. Babcock, Zachary Shriver, Bradley L. Pentelute, Obadiah Plante, David Skurnik

>READ

Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Sibeprenlimab in Healthy Participants

August 11, 2023 | Clinical Development in Drug Pharmacology

Xiaoyan Zhang, et. al.

Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Sibeprenlimab in Healthy Participants

Xiaoyan Zhang, Yanlin Wang, Jill Yarbrough, Mohit Mathur, Lee Andrews, Brian J G Pereira, Susan E Sloan, Asher D Schachter

>READ

Global Incidence of IgA Nephropathy by Race and Ethnicity: A Systematic Review

August 4, 2023 | Kidney360

Krzysztof Kiryluk et al.

Global Incidence of IgA Nephropathy by Race and Ethnicity: A Systematic Review

Krzysztof Kiryluk, Daniel E. Freedberg, Jai Radhakrishnan, Leslie Segall, Judith S. Jacobson, Mohit Mathur, Sumit Mohan, Alfred I. Neugut

>READ

The incidence and prevalence of IgA nephropathy in Europe

May 8, 2023 | Nephrology Dialysis Transplantation

Cynthia J. Willey et al.

The incidence and prevalence of IgA nephropathy in Europe

Cynthia J. Willey, Rosanna Coppo, Franz Schaefer, Malgorzata Mizerska-Wasiak, Mohit Mathur, Michaela J. Schultz

>READ

Multi-omic single cell sequencing: Overview and opportunities for kidney disease therapeutic development

April 5, 2023 | Frontiers in Molecular Biosciences

Steven Pregizer, et al.

Multi-omic single cell sequencing: Overview and opportunities for kidney disease therapeutic development

Steven Pregizer, Thom Vreven, Mohit Mathur, Luke Robinson

>READ

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VIS649 (Sibeprenlimab), an APRIL-Neutralizing IgG2 Monoclonal Antibody, in Healthy Volunteers

May 10, 2022 | Kidney International Reports

Mohit Mathur,et. al

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VIS649 (Sibeprenlimab), an APRIL-Neutralizing IgG2 Monoclonal Antibody, in Healthy Volunteers

Mohit Mathur, Jonathan Barratt, Yusuke Suzuki, Frank Engler, Marcela F. Pasetti, Jill Yarbrough, Susan Sloan, David Oldach

>READ

Modeling cell-specific dynamics and regulation of the common gamma chain cytokines

April 27, 2021 | Cell Reports

Ali M. Farhat et al.

Modeling cell-specific dynamics and regulation of the common gamma chain cytokines

Ali M. Farhat, Adam C. Weiner, Cori Posner, Zoe S. Kim, Brian Orcutt-Jahns, Scott M. Carlson, Aaron S. Meyer

>READ

Characterization of an Antibody Recognizing the Conserved Inner Core of Pseudomonas aeruginosa Lipopolysaccharides

November 3, 2020 | Biochemistry

Stefano Elli et al.

Characterization of an Antibody Recognizing the Conserved Inner Core of Pseudomonas aeruginosa Lipopolysaccharides

Stefano Elli, Anna Alekseeva, Boopathy Ramakrishnan, Tyree Koch, Andrew Wollacott, Karthik Viswanathan, Kai Li, James C Delaney, Zachary Shriver, Obadiah Plante, Marco Guerrini

>READ

VIS832, a novel CD138-targeting monoclonal antibody, potently induces killing of human multiple myeloma and further synergizes with IMiDs or bortezomib in vitro and in vivo

November 2, 2020 | Blood Cancer Journal

Tengteng Yu et al.

VIS832, a novel CD138-targeting monoclonal antibody, potently induces killing of human multiple myeloma and further synergizes with IMiDs or bortezomib in vitro and in vivo

Tengteng Yu, Bharat Chaganty, Liang Lin, Lijie Xing, Boopathy Ramakrishnan, Kenneth Wen, Phillip A Hsieh, Andrew Wollacott, Karthik Viswanathan, Hedy Adari, Shih-Feng Cho, Yuyin Li, Hailin Chen, Wenjuan Yang, Yan Xu, Gang An, Lugui Qiu, Nikhil Munshi, Gregory Babcock, Zachary Shriver, James R Myette, Kenneth C Anderson, Yu-Tzu Tai

>READ

Clinical and virological responses to a broad-spectrum human monoclonal antibody in an influenza virus challenge study

March 7, 2020 | Antiviral Research

Susan E Sloan et al.

Clinical and virological responses to a broad-spectrum human monoclonal antibody in an influenza virus challenge study

Susan E Sloan, Kristy J Szretter, Bharathi Sundaresh, Kristin M Narayan, Patrick F Smith, David Skurnik, Sylvain Bedard, José M Trevejo, David Oldach, Zachary Shriver

>READ